Saiontz & Kirk, P.A. is no longer investigating potential product liability involving the use of Chantix. This page is provided for informational purposes only.

Side effects of Chantix have been linked to a potential increased the risk of suicide or and a number of serious and life-threatening injuries. Thousands of lawsuits were pursued by individuals throughout the United States, with nearly all of the cases being settled in 2013.

According allegations raised in the complaints, Pfizer failed to adequately warn users prior to July 2009 about the increased risk of suicide, unusually aggressive behavior and other potential health risks that may be caused when the medication is used by individuals looking to improve their health by quitting smoking.

The Chantix lawyers at Saiontz & Kirk, P.A. previously were pursuing potential product liability lawsuits for individuals who suffered a severe physical injury or death that may be related to the use of Chantix, including cases for individuals who:

Potential Chantix cases are no longer being accepted by Saiontz & Kirk, P.A.


Chantix (varenicline tartrate) is sold by Pfizer as a smoking cessation drug to help ease the side effects of nicotine withdrawal and help people permanently stop smoking.  It was approved by the FDA in May 2006, and it quickly become a popular drug among individuals attempting to improve their overall health by kicking their nicotine addition.

Although the manufacturer introduced the medication with hopes that it would become a blockbuster prescription drug, Chantix problems began to surface at an alarming rate. During the years after it was first approved, Chantix became one of the drugs most associated with severe adverse events according to the FDA’s Adverse Event reporting system.

The active ingredient in Chatix acts on the brain, which has led to a number of problems and psychological side effects, which the manufacturer initially failed to adequately research or warn about. 

In 2009, the FDA required Pfizer to add stronger information to the warning label about a possible increased risk of suicide, suicidal thoughts and abnormal behavior from Chantix.  However, lawsuits were also reviewed at various times for a number of other Chantix problems that have caused severe injury or death for a number of users.

In June 2011, the FDA required new warnings about an increased risk of heart attacks and other heart problems with Chantix. Although Pfizer had access to information which may have demonstrated this risk earlier, they failed to adequately research the medication or warn consumers and the medical community.


Individual cases and potential Chantix class action suits were pursued as a result of Pfizer’s failure to properly warn consumers and investigate problems associated with their medication.  Pfizer’s actions seemed to indicate that the company was primarily concerned with protecting the potential profits, even at the expense of the health of consumers who are trying to quit smoking to prolong their lives.